JNJ-77242113

Phase 3Small molecule

Johnson & Johnson

JNJ-77242113 is one of 70 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Plaque PsoriasisActive, not recruiting

Generalized Pustular PsoriasisActive, not recruiting

PsoriasisPhase 3

Active, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Plaque PsoriasisPhase 3

Active, not recruiting

Generalized Pustular PsoriasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

JNJ-77242113

Johnson & Johnson

Phase 3

3 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06095102

Q2 2027

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06095115

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06143878

Q3 2027

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06934226

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06220604

Q4 2027

Phase 3Active, not recruiting

Generalized Pustular Psoriasis

NCT06295692

Clinical

Trials by Indication[1]

Plaque Psoriasis5 trials

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06220604·731 enrolled

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06143878·774 enrolled

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06095102·311 enrolled

Show 2 more trials

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06095115·684 enrolled

77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06934226·752 enrolled